Table 3.
Treatment outcomes of patients with brachytherapy for cervical cancer.
| Event Outcome | Squamous Cell Carcinoma | % | Adeno-Carcinoma | % | Total | % | p * |
|---|---|---|---|---|---|---|---|
| (n = 107) | (n = 28) | (n = 135) | |||||
| Local failure | 5 | 4.70% | 7 | 25.00% | 12 | 8.90% | 0.003 |
| - Persistent disease | 2 | 1.90% | 5 | 17.90% | 7 | 5.20% | |
|
1 | 0.90% | 3 | 10.70% | 4 | 3.00% | |
| - Local recurrence after remission | 3 | 2.80% | 2 | 7.10% | 5 | 3.70% | |
| Pelvic failure | 10 | 9.30% | 10 | 35.70% | 20 | 14.80% | 0.001 |
| - Pelvic lymph node recurrence | 5 | 4.70% | 3 | 10.70% | 8 | 5.90% | |
| Distant failure | 15 | 14.00% | 9 | 32.10% | 24 | 17.80% | 0.048 |
| - Subsequent systemic treatment | 14 | 13.10% | 7 | 25.00% | 21 | 15.60% | |
| Death | 6 | 5.60% | 8 | 28.60% | 14 | 10.40% | 0.002 |
* The p-values represent the comparison of the overall number of events for each survival outcome by histology.